Filana Burns $12.7M in H1, Guides to $36-40M Year-End Cash Amid Clinical Hold
FLNA is trading near its 52-week low of $0.88 (3.5% above the low).
Summary
Filana reported Q2 2026 results with cash of $82.7M, down from $95.5M at year-end, and H1 operating cash burn of $12.7M—below prior guidance. The company guided to H2 cash use of $11-15M plus a $31.25M litigation settlement payment, leaving year-end unrestricted cash at just $36-40M. That's a tight runway for a biotech with its lead program under a full clinical hold since May. The FDA hold on the TSC-related epilepsy trial remains unresolved, with the company still working to address information requests. A $31.25M securities litigation settlement was funded into escrow on July 23, a step toward final resolution but a significant drain on resources. With shares at $0.91 near the 52-week low and a market cap of $43M, the cash position and clinical uncertainty keep this high-risk. The TSC World Conference this week may provide community engagement but no regulatory clarity.
At the time of this announcement, FLNA was trading at $0.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $42.7M. The 52-week trading range was $0.88 to $4.98. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.